(Reuters) – Merck Canada and a group of pharmaceutical companies are challenging the constitutionality of a new regulation that intends to lower patented drug prices, the company said in a Friday statement, a revised reform proposal that would undermine the earnings of pharmaceutical companies. dissolution.
The Canadian government announced final regulations giving new powers to the Patent Medical Price Review Board (PMPRB) earlier this month, and published them in an official program on Wednesday. They shall enter into force on 1 July, 2020.
“Our position is that the federal government has no constitutional authority to regulate the prices of medicines and to manage healthcare systems, which have always been a provincial jurisdiction,” said Merck Canada, and the new rules will “Delay and limit access to new medicines by Canadians. ”
Health Canada, Canada's federal health department, did not respond immediately to a request for views.
The filing filing is affecting the liberal government of Prime Minister Justin Trudeau and the pharmaceutical industry ahead of a national election in October.
Drug manufacturers, who are represented in Canada by a Canadian Innovative Medicines lobby group, argued that lower prices would delay drug launch, reduce investment in life sciences and drive new drug trials out of the country.
Allison Martell reporting in Toronto; additional reporting by Kelsey Johnson in Ottawa; edited by Chris Reese and Jonathan Oatis
. and Medical Research (TRBC) (t) Pharmaceutical and Medical Research (TRBC) (t) Canada (t) USA